Asare Elliot A, Evans Douglas B, Erickson Beth A, Aburajab Murad, Tolat Parag, Tsai Susan
Pancreatic Cancer Program, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
J Surg Oncol. 2016 Sep;114(3):291-5. doi: 10.1002/jso.24316. Epub 2016 Jun 6.
Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291-295. © 2016 Wiley Periodicals, Inc.
可切除胰腺癌的治疗顺序仍存在争议，且缺乏比较新辅助治疗与辅助治疗策略的一级证据。然而，对这些治疗策略的成本效益分析进行比较，可能有助于更好地界定每种方法的医疗价值。本综述将强调胰腺癌多模式治疗的基本原理，讨论辅助治疗的优缺点，并就医疗价值概念化新辅助治疗方法的成本效益。《外科肿瘤学杂志》2016年；114:291 - 295。©2016威利期刊公司。
